Drug intelligence / Profile preview

SWIFT Discovery Engine Program 1

Development stage: Unknown
Lead developer: Forward Therapeutics

Overview

SWIFT Discovery Engine Program 1 is an early-stage drug discovery program developed by Forward Therapeutics. The program utilizes the company's proprietary SWIFT (Structure-based drug discovery With Integrated Fast-cycle Technology) discovery engine to identify and develop novel therapeutic candidates. While the specific biological targets, modalities, and primary indications remain undisclosed, the program is focused on expanding Forward Therapeutics' pipeline beyond its lead TNF signaling inhibitors. The program is currently in the discovery phase of development, targeting inflammatory and autoimmune conditions.

Other names: Forward Therapeutics-multiple undisclosed targets

Targets

Tumor necrosis factor receptor 1 (TNFR1)–soluble tumor necrosis factor (sTNF) trimer signaling complex

Beyond the preview

Go deeper on SWIFT Discovery Engine Program 1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SWIFT Discovery Engine Program 1.

Explore the full profile